- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT00084708
Calcitriol and Gefitinib With or Without Dexamethasone in Treating Patients With Advanced Solid Tumors
A Phase I Study of Intravenous (IV) Calcitriol in Combination With ZD1839 (IRESSA®) in Refractory Solid Tumors
RATIONALE: Gefitinib may stop the growth of tumor cells by blocking the enzymes necessary for their growth. Calcitriol may help tumor cells develop into normal cells. Dexamethasone may increase the effectiveness and decrease the side effects of gefitinib and calcitriol.
PURPOSE: This phase I trial is studying the side effects and best dose of calcitriol when given together with gefitinib or when given together with gefitinib and dexamethasone in treating patients with advanced solid tumors.
Studie Overzicht
Toestand
Interventie / Behandeling
Gedetailleerde beschrijving
OBJECTIVES:
Primary
- Determine the maximum tolerated dose (MTD), toxic effects, and tolerability of calcitriol alone and in combination with gefitinib with or without dexamethasone in patients with advanced solid tumors.
Secondary
- Determine the pharmacokinetics and pharmacodynamics of these regimens in these patients.
- Determine any tumor responses in patients treated with these regimens.
OUTLINE: This is a dose-escalation study of calcitriol.
- Stage 1: Patients receive calcitriol IV over 1 hour on days 1, 15, and 22 and oral gefitinib once daily on days 8-28 during course 1. For all subsequent courses, patients receive calcitriol IV over 1 hour on days 1, 8, 15, and 22 and oral gefitinib once daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Cohorts of 3-6 patients receive escalating doses of calcitriol with a fixed dose of gefitinib until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity.
- Stage 2: Patients receive calcitriol (beginning at 1 dose level below the MTD determined in stage 1) and gefitinib as in stage 1. Patients also receive oral dexamethasone once on the day before and twice on the day of each dose of calcitriol.
Cohorts 3-6 patients receive escalating doses of calcitriol with fixed doses of gefitinib and dexamethasone until the MTD is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity.
PROJECTED ACCRUAL: A total of 21-36 patients will be accrued for this study within 1 year.
Studietype
Inschrijving (Werkelijk)
Fase
- Fase 1
Contacten en locaties
Studie Locaties
-
-
New York
-
Buffalo, New York, Verenigde Staten, 14263-0001
- Roswell Park Cancer Institute
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
DISEASE CHARACTERISTICS:
Histologically confirmed advanced solid tumor
- Metastatic or unresectable disease
- Standard curative or palliative measures do not exist or are no longer effective
- No known brain metastases
PATIENT CHARACTERISTICS:
Age
- 18 and over
Performance status
- ECOG 0-2 OR
- Karnofsky 60-100%
Life expectancy
- More than 3 months
Hematopoietic
- WBC ≥ 3,000/mm^3
- Hemoglobin ≥ 8 g/dL
- Absolute neutrophil count ≥ 1,500/mm^3
- Platelet count ≥ 100,000/mm^3
Hepatic
- Bilirubin normal
- AST and ALT ≤ 2.5 times upper limit of normal
- No unstable or uncompensated hepatic disease
Renal
- Creatinine normal OR
- Creatinine clearance ≥ 60 mL/min
- No prior hypercalcemia
- No kidney, ureteral, or bladder stones within the past 10 years
- No unstable or uncompensated renal disease
Cardiovascular
- Ejection fraction ≥ 30%
- No heart failure or significant heart disease
- No significant arrhythmias
- No myocardial infarction within the past 3 months
- No unstable angina pectoris
- No symptomatic congestive heart failure
- No other unstable or uncompensated cardiac disease
Pulmonary
No evidence of clinically active interstitial lung disease
- Chronic, stable, asymptomatic, radiographic changes allowed
- No other unstable or uncompensated respiratory disease
Other
- Not pregnant or nursing
- Negative pregnancy test
- Fertile patients must use effective contraception during and for 30 days after study treatment
- Able to receive oral medication
- Willing to have serial skin biopsies
- No prior allergic reaction to compounds of similar chemical or biological composition to study drugs or other agents used in this study
- No ongoing or active infection
- No known severe hypersensitivity to gefitinib or any of its excipients
- No psychiatric illness or social situation that would preclude study compliance
- No other severe or uncontrolled systemic disease or concurrent illness that would preclude study participation
- No other significant clinical disorder or laboratory finding that would preclude study participation
PRIOR CONCURRENT THERAPY:
Biologic therapy
- No concurrent filgrastim (G-CSF) or sargramostim (GM-CSF)
Chemotherapy
- More than 4 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin) and recovered
Endocrine therapy
- No other concurrent systemic glucocorticoid therapy
Radiotherapy
- More than 4 weeks since prior radiotherapy and recovered
Surgery
- Recovered from prior major surgery
- No prior nephrectomy
Other
- Recovered from all prior anticancer therapy
- More than 30 days since prior non-approved or investigational drugs
- More than 7 days since prior thiazides
No concurrent administration of any of the following:
- Combination antiretroviral therapy for HIV-positive patients
- Phenytoin
- Carbamazepine
- Barbiturates
- Rifampin
- Phenobarbital
- Hypericum perforatum (St. John's wort)
- Calcium supplements
- Thiazides
- Digoxin
- No other concurrent investigational or commercial anticancer agents or therapies
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: NVT
- Interventioneel model: Opdracht voor een enkele groep
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
---|
Maximaal getolereerde dosis
|
Medewerkers en onderzoekers
Sponsor
Onderzoekers
- Hoofdonderzoeker: Marwan Fakih, MD, Roswell Park Cancer Institute
Studie record data
Bestudeer belangrijke data
Studie start
Primaire voltooiing (Werkelijk)
Studie voltooiing (Werkelijk)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Schatting)
Updates van studierecords
Laatste update geplaatst (Schatting)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Aanvullende relevante MeSH-voorwaarden
- Neoplasmata
- Fysiologische effecten van medicijnen
- Moleculaire mechanismen van farmacologische werking
- Autonome agenten
- Agenten van het perifere zenuwstelsel
- Enzymremmers
- Ontstekingsremmende middelen
- Antineoplastische middelen
- Anti-emetica
- Gastro-intestinale middelen
- Glucocorticoïden
- Hormonen
- Hormonen, hormoonvervangers en hormoonantagonisten
- Antineoplastische middelen, hormonaal
- Micronutriënten
- Membraantransportmodulatoren
- Proteïnekinaseremmers
- Vitaminen
- Behoudsmiddelen voor botdichtheid
- Calciumregulerende hormonen en middelen
- Vasoconstrictieve middelen
- Calciumkanaalagonisten
- Dexamethason
- Gefitinib
- Calcitriol
Andere studie-ID-nummers
- CDR0000365546
- RPCI-RPC-0207
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .
Klinische onderzoeken op dexamethason
-
Ottawa Hospital Research InstituteVoltooidPijn syndroom | Borstkanker in een vroeg stadiumCanada
-
Universitätsklinikum Hamburg-EppendorfGemeinsamer Bundesausschuss (G-BA); Staburo GmbHWerving
-
Vanderbilt University Medical CenterBeëindigdAstma | KruisVerenigde Staten
-
Shanghai Jiao Tong University Affiliated Sixth...VoltooidAnalgesie | Tijd | Brachiaal Plexus Blok | Schouder Chirurgie | Dexamethason | Intraveneus drugsgebruikChina
-
Centre hospitalier de l'Université de Montréal...VoltooidPreventie van overgevoeligheidsreacties op paclitaxelCanada
-
Dr. Stephen ChoiThe Physicians' Services Incorporated FoundationVoltooidSchouder Chirurgie | Zenuw blokCanada
-
Poznan University of Medical SciencesWervingPols verwondingen | Hand verwondingen | Handverwondingen en aandoeningen | Handziekte | Pols ziektePolen
-
University of BelgradeVoltooid
-
General Hospital of Ningxia Medical UniversityNog niet aan het werven
-
Cairo UniversityOnbekend